Axcelis

Axcelis has a defensible position in ion implantation, underpinned by process know‑how, patents, and an installed base exceeding 3,400 tools across 27 countries which anchors a recurring CS&I stream.

Competitively, only Applied Materials offers a full implant portfolio; Japanese (Nissin, Sumitomo) and Chinese (ABT, Kingstone, CETC) vendors target niches and China localization, respectively.

Moat components: Switching costs 80/100 driven by recipes, tool‑by‑tool process integration, and fab qualifications; Efficient scale 75/100 given the concentrated, oligopolistic market; Intangibles 70/100 through patents and brand credibility (169 US and 356 ex‑US active patents as of 12/31/25); Cost advantage 55/100 as a focused pure‑play with lean capex needs but smaller scale than AMAT; Network effects 30/100 are limited.

Weighted result supports a narrow but meaningful moat subject to geopolitical and technology‑mix pressure.